1. 1The European Agency for the Evaluation of Medicinal Products/Committee for Proprietary Medical Products (CPMP) Biotechnology Working Party, Ad-Hoc Working Group on Blood Products : Workshop on Viral Safety of Plasma-Derived Medicinal Products with Particular Focus on Non-Enveloped Viruses. CPMP/BWP/BPWG/4080/00. 2001 http://www.emea.eu.int/index/indexh1.htm
2. 2The European Agency for the Evaluation of Medicinal Products/Committee for Proprietary Medical Products (CPMP) Biotechnology Working Party, Ad-Hoc Working Group on Blood Products : Guideline on Assessing the Risk for Virus Transmission - New Chapter 6 of the Note for Guidance on Plasma-derived Medicinal Products (CPMP/BWP/269/95). CPMP/BWP/5180/03. 2004 http://www.emea.eu.int/index/indexh1.htm
3. 3Pharmaceutical and Food Safety Bureau, Ministry of Health, Labour and Welfare : Guideline on the look-back review of blood products. Ref. No. 0310011 (10th March 2005). Tokyo, Japan, Pharmaceutical and Food Safety Bureau, Ministry of Health, Labour and Welfare. [in Japanese]
4. Inactivation of parvovirus B19 during pasteurization of human serum albumin
5. Heat sensitivity of human parvovirus B19